These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 16404620)

  • 1. Comparing costs and effectiveness of different starting points for highly active antiretroviral therapy in HIV-positive patients. Evidence from the ICONA cohort.
    Merito M; Pezzotti P;
    Eur J Health Econ; 2006 Mar; 7(1):30-6. PubMed ID: 16404620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.
    Badri M; Cleary S; Maartens G; Pitt J; Bekker LG; Orrell C; Wood R
    Antivir Ther; 2006; 11(1):63-72. PubMed ID: 16518961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. When to initiate highly active antiretroviral therapy in low-resource settings: the Moroccan experience.
    Loubiere S; el Filal KM; Sodqi M; Loundou A; Luchini S; Cleary S; Moatti JP; Himmich H
    Antivir Ther; 2008; 13(2):241-51. PubMed ID: 18505175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001.
    Beck EJ; Mandalia S; Gaudreault M; Brewer C; Zowall H; Gilmore N; Klein MB; Lalonde R; Piché A; Hankins CA
    AIDS; 2004 Dec; 18(18):2411-8. PubMed ID: 15622317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Setting a minimum threshold CD4 count for initiation of highly active antiretroviral therapy in HIV-infected patients.
    Ho C; Lee S; Wong Kh; Cheng L; Lam M
    HIV Med; 2007 Apr; 8(3):181-5. PubMed ID: 17461862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
    Lapadula G; Torti C; Maggiolo F; Casari S; Suter F; Minoli L; Pezzoli C; Di Pietro M; Migliorino G; Ouiros-Roldan E; Ladisa N; Sighinolfi L; Costarelli S; Carosi G;
    Antivir Ther; 2007; 12(6):941-7. PubMed ID: 17926648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.
    Laurichesse JJ; Persoz A; Theodorou I; Rouzioux C; Delfraissy JF; Meyer L
    HIV Med; 2007 May; 8(4):213-9. PubMed ID: 17461848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients' preferences regarding the timing of highly active antiretroviral therapy initiation for chronic asymptomatic HIV-1 infection.
    Locadia M; van Grieken RA; Prins JM; de Vries HJ; Sprangers MA; Nieuwkerk PT
    Antivir Ther; 2006; 11(3):335-41. PubMed ID: 16759050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of antiretroviral treatment in a South African program: a cohort study.
    Fairall LR; Bachmann MO; Louwagie GM; van Vuuren C; Chikobvu P; Steyn D; Staniland GH; Timmerman V; Msimanga M; Seebregts CJ; Boulle A; Nhiwatiwa R; Bateman ED; Zwarenstein MF; Chapman RD
    Arch Intern Med; 2008 Jan; 168(1):86-93. PubMed ID: 18195200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
    Patel K; Hernán MA; Williams PL; Seeger JD; McIntosh K; Van Dyke RB; Seage GR;
    Clin Infect Dis; 2008 Feb; 46(4):507-15. PubMed ID: 18199042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of "HAART" on CD4+ T lymphocyte counts in HIV seropositive south-Indian individuals--a follow up study.
    Shahapur PR; Bairy I; Shivananda PG
    Indian J Pathol Microbiol; 2005 Apr; 48(2):270-2. PubMed ID: 16758693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes and immune reconstitution in 103 advanced AIDS patients undergoing 12-month highly active antiretroviral therapy.
    Dai Y; Qiu ZF; Li TS; Han Y; Zuo LY; Xie J; Ma XJ; Liu ZY; Wang AX
    Chin Med J (Engl); 2006 Oct; 119(20):1677-82. PubMed ID: 17097013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accounting for leadtime in cohort studies: evaluating when to initiate HIV therapies.
    Cole SR; Li R; Anastos K; Detels R; Young M; Chmiel JS; Muñoz A
    Stat Med; 2004 Nov; 23(21):3351-63. PubMed ID: 15493031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently <500 copies/mL during treatment with antiretroviral drugs.
    Le Moing V; Thiébaut R; Chêne G; Sobel A; Massip P; Collin F; Meyohas M; Al Kaïed F; Leport C; Raffi F;
    HIV Med; 2007 Apr; 8(3):156-63. PubMed ID: 17461859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of malnutrition on survival and the CD4 count response in HIV-infected patients starting antiretroviral therapy.
    Paton NI; Sangeetha S; Earnest A; Bellamy R
    HIV Med; 2006 Jul; 7(5):323-30. PubMed ID: 16945078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Highly active antiretroviral therapy in HIV sero-positive children. Disease progression by baseline clinical, immunological and virological status].
    Rodríguez de Schiavi MS; Scrigni A; García Arrigoni P; Bologna R; Barboni G; Redondo J; Nastri M; Mecikovsky D; Cantisano C; Moreno R; Siciliani D; Lencina M; Luedicke N; Rezzónico G; Torolla JL; López Papucci S; Luis M; Libonati C; Gamba L; Barbarysky J; Pérez Hernández E; Zlatkes R
    Arch Argent Pediatr; 2009 Jun; 107(3):212-20. PubMed ID: 19543629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of maintaining highly active antiretroviral therapy on AIDS events among patients with late-stage HIV infection and inadequate response to therapy.
    Gandhi T; Wei W; Amin K; Kazanjian P
    Clin Infect Dis; 2006 Mar; 42(6):878-84. PubMed ID: 16477568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structured treatment interruptions following immediate initiation of HAART in eight patients with acute HIV-1 seroconversion.
    Vogel M; Lichterfeld M; Kaufmann DE; Mui SK; Altfeld M; Voigt E; Ahlenstiel G; Kupfer B; Walker B; Spengler U; Rockstroh JK
    Eur J Med Res; 2006 Jul; 11(7):273-8. PubMed ID: 16899420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD; Keruly JC
    Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.